Kyverna Therapeutics begins participants enrolment in Phase I KYV-101 trial

Kyverna Therapeutics has enrolled the first participant in its Phase I clinical trial of KYV-101 to treat lupus nephritis (LN) in the US.

The dose escalation, open-label, multi-centre Phase I clinical trial has been designed for evaluating KYV-101’s safety in refractory LN patients.

Approximately nine to 12 LN patients across the US are expected to be enrolled in the trial.

A new, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, KYV-101 has been designed for use in B cell-driven autoimmune diseases, such as LN.

It specifically targets CD19, which is a protein that is expressed on the B cell’s surface.

B cells are involved in many types of malignancies, including autoimmune diseases.

The company expects that its investigational CAR T-cell therapy may offer new hope for those patients who have exhausted tapping the conventional treatment options.

Kyverna Therapeutics CEO Peter Maag said: “We are immensely proud to have reached this significant milestone in our journey to transform the lives of patients battling life-altering ailments such as LN.

“Our KYV-101 cell therapy has the potential to revolutionise treatment for individuals suffering from autoimmune diseases, with patients currently being treated for multiple indications across the US and Europe.

“We look forward to advancing our clinical programmes so we can bring a new option to patients as quickly as possible.”

In November last year, the company received clearance for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to start the Phase I clinical trial of KYV-101 for LN treatment.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell...

Read more

Thank you.

You will receive an email shortly. Please check your inbox to download the Whitepaper.

By Cytiva Thematic

You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our privacy policy.